Hansa Biopharma receives positive opinion for transplant asset in EU: "Amazing"
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommends conditional approval of Hansa Biopharma's main asset Idefirix in EU. The Swedish biotech firm expects to launch the drug by approximately fourth quarter of 2020.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY IDA LØJMAND
Listed Swedish biotech firm Hansa Biopharma is one big step closer to a market authorization of the company's candidate Idefirix (imlifidase) that helps kidney transplant patients prepare for the transplant.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
